In February 2016, AstraZeneca made a multibillion-dollar investment in Acerta Pharma for 55% ownership, driven by the lead Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib and the opportunity to build out its hematology/oncology pipeline. AstraZeneca holds the option to purchase the remainder of Acerta Pharma and complete a full acquisition.
Acerta Pharma’s discovery and research teams, which focus on developing new molecular entities, are based in Oss, The Netherlands. The group there was responsible for the discovery of acalabrutinib. Our largest site, which includes clinical operations, medical science, regulatory, safety, compliance, biostatistics, medical affairs and US administration is located in South San Francisco, CA.
The acalabrutinib program includes multiple clinical trials for both monotherapy and in combination with other targeted molecules. Over 200 employees are engaged in the development of acalabrutinib and other pipeline compounds for hematologic malignancies.
Plans to expand the oncology program include testing other targeted compounds in combination with acalabrutinib in a variety of blood-based oncology indications.
Board of Directors
Acerta Pharma thanks its founders for their efforts, sacrifices and dedication to bringing acalabrutinib to patients.
Ahmed Hamdy, MD
Allard Kaptein, PhD
Raquel Izumi, PhD
Tjeerd Barf, PhD
Finance & Operations
Chief Executive Officer
Jurriaan Dekkers is Chief Executive Officer (CEO) and Board Member of Acerta Pharma BV and Chief Financial Officer (CFO) for AstraZeneca BV in the Netherlands. In addition, he is Director for all AstraZeneca Holding companies in the Netherlands.
Jurriaan holds an MSc. in Economics from Erasmus University Rotterdam, the Netherlands (2001) and is a Certified Public Auditor (Register Accountant, RA) graduate from the Erasmus University Rotterdam (2004). After finishing his Economics, Jurriaan worked for 12 years at PwC, serving international clients in the area of Assurance and Mergers & Acquisitions. During this period, Jurriaan also worked for PwC internationally.
After his career with PwC, Jurriaan decided to move into business. He worked for several years in European and Global finance roles within Sandvik and as Finance Director EMEA within DaVita Medical Group. In 2018, Jurriaan started as CFO for AstraZeneca in the Netherlands.
Andrew Mortlock, PhD
Chief Scientific Officer
Dr Mortlock joins Acerta from his duties as Vice President, Global Projects and Alliances, IMED Oncology at AstraZeneca, where he is responsible for AstraZeneca’s small molecule oncology projects from start of lead optimization through to the end of Phase IIb clinical studies. Over 25 years in roles of increasing responsibility at AstraZeneca, he previously led the Oncology research group at Alderley Park (UK) and Reims (France) which included chemistry, bioscience and drug metabolism. He brings a wealth of medicinal chemistry, global development and project leadership experience involving kinase, protease, integrin, GPCR, nuclear hormone receptor and protein-protein interaction targets.
Dr Mortlock holds a first degree in chemistry and a PhD in organic synthesis from the University of Oxford and carried out post-doctoral work at the University of California, Berkeley. He has been an author on more than 50 scientific papers, patents and presentations.
Vice President, R&D Oncology Unit
Mark joined Acerta pharma in June of 2017 as Executive Director, Head of Clinical Science to lead the Acerta clinical science group for late-stage oncology-hematology.
Mark is a clinical development professional with over 20 years of experience in Oncology (Hematology, Immuno-oncology, and Solid Tumors). Mark has lead development teams as the Head of Clinical Operation at Corvus, Oncology Operation Lead at Gilead and the Hematology Disease Area Lead at Roche/Genentech. Mark has led both early and late-stage global development teams leading to successful clinical strategies and resulting in global regulatory filings in hematology/oncology for Rituxan/MabThera, Gazyva, and Venetoclax.
Sr. Director, Head of Finance
Mauricio has more than 15 years of professional experience in several business and financial leadership functions. Mauricio received his Bachelor of Finance in 1999 from the Universidad Panamericana and MBA from Universidad Anahuac in 2004 in Mexico City.
Mauricio joined AstraZeneca as FP&A Manager in Mexico and gained significant commercial experience in roles in the United Kingdom and Germany. He is known for his passion to be a strategic and tactical business partner and building high-performance teams.
Mauricio served as the CFO for CAMCAR MAC (Central America, Caribbean and Mid Andean Countries) based in Costa Rica where his responsibilities extended well beyond Finance. He relocated to Gaithersburg, MD, USA to join the GPPS area as the Therapeutic Area Finance Director for Infection, Neuroscience and Autoimmunity (INA) continuing to deliver additional value to mature brands and supported diverse initiatives for the pipeline portfolio, including TA strategy and portfolio prioritization.
Prior to joining AstraZeneca, Mauricio worked for companies such as General Electric, British Petroleum and the Mexican Stock Exchange in the areas of Planning and Financial Performance. During his free time Mauricio enjoys traveling, photography and playing soccer with his two boys.
Executive Director and Chief Executive Officer – AstraZeneca Plc
Dr Soriot brings significant experience in established and emerging markets, strength of strategic thinking, a successful track record of managing change and executing strategy, and the ability to lead a diverse organization. He served as Chief Operating Officer of Roche’s pharmaceuticals division from 2010 to September 2012 and, prior to that, Chief Executive Officer of Genentech, a biologics business, where he led its successful merger with Roche. Pascal joined the pharmaceutical industry in 1986 and has worked in senior management roles in numerous major companies around the world. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.
Executive Director and Chief Financial Officer – AstraZeneca Plc
Mr Dunoyer’s career in pharmaceuticals, which has included periods with Roussel Uclaf, Hoechst Marion Roussel and GlaxoSmithKline (GSK), has given him extensive industry experience, including finance and accounting; corporate strategy and planning; research and development; sales and marketing; business reorganization; and business development. Marc is a qualified accountant and joined AstraZeneca in 2013, serving as Executive Vice-President, GPPS from June to October 2013. Prior to that, he served as Global Head of Rare Diseases at GSK and (concurrently) Chairman, GSK Japan. He holds an MBA from HEC, Paris and a Bachelor of Law degree from Paris University.
Nico Stam, PhD, MBA
Vice President Europe & Site Head Acerta Oss, Netherlands
Dr Stam joined Acerta Pharma in January 2018 as Vice President Research Europe & Site Head of Acerta’s R&D site in The Netherlands. Dr Stam has over 25 years of experience in pharmaceutical industry, and held executive positions in business development & licensing, R&D portfolio management, strategy, merger & acquisition research, and R&D at Merck & Co, Schering-Plough, and Organon.
Furthermore, as business lead, he played a pivotal role in setting up fundraising activities for, several biotech start-ups and spin-out companies. In several of these companies, he served as interim CEO, or member of the advisory board.
Dr Stam received an MSc degree in Chemistry, and a PhD in immunology/cancer research from the Free University Amsterdam & Netherlands Cancer Institute. Furthermore, he holds a Master's degree in Business Administration (MBA) and is a Certified Licensing Professional (CLP™).